莱菔硫烷
糖酵解
癌症研究
过剩1
氧化磷酸化
厌氧糖酵解
化学
膀胱癌
癌细胞
癌症
葡萄糖转运蛋白
下调和上调
碳水化合物代谢
己糖激酶
新陈代谢
内科学
内分泌学
生物化学
生物
医学
胰岛素
基因
作者
Lei Huang,Canxia He,Sicong Zheng,Chao Wu,Mulan Ren,Yujuan Shan
标识
DOI:10.1002/mnfr.202100738
摘要
Metabolic disorder is a pivotal hallmark of cancer cells. Sulforaphane (SFN) is reported to improve lipid metabolism. However, the effect of SFN on glucose metabolism in bladder cancer remains unclear. Hence, the effect and underling mechanism is investigated.Biological samples from bladder cancer patients are collected, and also investigated using N-butyl-N-(4-hydroxybutyl) nitrosamine-induced bladder cancer mice and bladder cancer cell lines. A novel glucose transport aberrant-independent aerobic glycolysis is found in bladder cancer patients, and the lower malignancy tissues have the more obvious abnormality. SFN strongly downregulates ATP production by inhibiting glycolysis and mitochondrial oxidative phosphorylation (OXPHOS). Both in vitro cell culture and in bladder tumor mice, SFN weaken the glycolytic flux by suppressing multiple metabolic enzymes, including hexokinase 2 (HK2) and pyruvate dehydrogenase (PDH). Moreover, SFN decreases the level of AKT1 and p-AKT ser473 , especially in low-invasive UMUC3 cells. The downregulation of ATP and HK2 by SFN is both reversed by AKT1 overexpression.SFN downregulates the unique glucose transport aberrant-independent aerobic glycolysis existed in bladder cancer via blocking the AKT1/HK2 axis and PDH expression.
科研通智能强力驱动
Strongly Powered by AbleSci AI